Loading
A year of two targeted pills after surgery halves the risk of relapse in BRAF-mutant melanoma, and the benefit is still visible a decade later.
RFS HR 0.47 at first analysis; final analysis (JCO 2024, >10 years) reported 10-year RFS 48% vs 32% and DMFS 63% vs 48%. OS analysis was hampered by crossover and subsequent immunotherapy. The longest follow-up of any adjuvant melanoma trial; the alternative to adjuvant PD-1 for BRAF-mutant patients.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
870 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Relapse-free survival at 10 yearsprimary | Dabrafenib + trametinib | - | 48% | - | - | link |
| Placebo | - | 32% | ||||
| Distant metastasis-free survival at 10 years | Dabrafenib + trametinib | - | 63% | - | - | link |
| Placebo | - | 48% |
A second publication from the COMBI-AD trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
Adjuvant dabrafenib-trametinib is a standard for resected stage III BRAF-mutant melanoma alongside adjuvant PD-1 blockade; the choice weighs a finite year of oral therapy against immune side effects.
Shares Georgina V. Long, Test intermittent dosing of targeted drugs to delay resistance, with honest priors, Dabrafenib, Dabrafenib + trametinib.
Shares Dabrafenib, Dabrafenib + trametinib, Trametinib, BRAF.
Shares Dabrafenib, Trametinib, Novartis, Small-molecule kinase inhibitors.
Shares Dabrafenib, Dabrafenib + trametinib, Trametinib, BRAF.
Shares Test intermittent dosing of targeted drugs to delay resistance, with honest priors, BRAF V600-mutant melanoma, BRAF, RAS / RAF / MEK / ERK (MAPK).
Shares Dabrafenib + trametinib, BRAF V600-mutant melanoma, BRAF, Melanoma.
Shares Test intermittent dosing of targeted drugs to delay resistance, with honest priors, BRAF V600-mutant melanoma, BRAF, RAS / RAF / MEK / ERK (MAPK).
Shares Dabrafenib + trametinib, BRAF V600-mutant melanoma, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, BRAF.